AI-generated analysis. Always verify with the original filing.
Alkermes plc completed the acquisition of Avadel Pharmaceuticals plc for $21.00 per share in cash plus a contingent value right (CVR). To finance the $1.525 billion transaction, Alkermes entered into new senior secured term loan facilities and terminated a prior bridge agreement.
Event Type
Disclosure
Mandatory
Variant
8-K
above. The foregoing description of the Credit Agreement set forth in Item 1.01 and the full text of the Credit Agreement, a copy of which is filed herewith as
. References to the Transaction Agreement or the Original Transaction Agreement from and after the entry into the Amendment on November 18, 2025 refer to the Or
. On February 12, 2026, we terminated the previously disclosed Bridge Credit Agreement entered into in order to fund the Acquisition, as described in Item 1.02
. The information in this Item 7.01, and in Exhibit 99.1 furnished herewith, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or othe
(b) is not included in this Current Report on Form 8-K. The Company intends to file such pro forma financial information by amendment to this Current Report on
Acquisition / Disposition
Material Agreement
Debt / Financing